Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

- Conference Call Scheduled for Today at 5:00 p.m. EDT -

SOUTH SAN FRANCISCO, Calif., April 1 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008.

Total revenue for the year ended December 31, 2008 was $5.4 million, with a net loss of $37.2 million. As of December 31, 2008, cash, cash equivalents and marketable securities totaled $10.6 million, with no outstanding debt. Sunesis Pharmaceuticals separately announced today the execution of a securities purchase agreement with accredited investors, including certain members of management, providing for a private placement, subject to the satisfaction of conditions, of up to $43.5 million in a tranched financing, including two tranches of units consisting of convertible preferred stock and common stock warrants, and a tranche of common stock.

Recent Highlights

  • Presented interim clinical data of the Phase 2 voreloxin single-agent REVEAL-1 trial at the 50th Annual Meeting of the American Society of Hematology, with a year end update that coincided with the 27th Annual J.P. Morgan Healthcare Conference in San Francisco. The REVEAL-1 trial is enrolling newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Schedules A (72 mg/m2 of voreloxin weekly for three weeks) and B (72 mg/m2 of voreloxin weekly for two weeks) are fully enrolled, and patients are now being enrolled on Schedule C (72 mg/m2 of voreloxin on days one and four). In Schedule A, twelve of 29 patients achieved complete remission (CR) or complete remission without full platelet recovery (CRp) with a 30-day all-cause mortality of 17%. An update of the interim data suggests that Schedule B is better tolerated
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
(Date:2/27/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is to ... BNC105 in patients with metastatic renal cancer at the ... . The data will be presented by Dr. ... Comprehensive Cancer Center in California ... data identifies Ferritin and IL-8 as two baseline biomarkers ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
(Date:2/26/2015)... 26, 2015  23andMe, the leading personal genetics company, ... as Privacy Officer and Corporate Counsel. Black brings a ... as well as health care regulations. As a member ... responsible for reviewing, updating and enhancing the company,s privacy ... abroad. She joined the company January 5, 2015 and ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 223andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2
... Oct. 12 /PRNewswire/ - Products incoporating micro and nano ... integrating new functionality for the world market. On Oct ... bent on taking state of the art products incorporating ... converge on Lake Louise. This is business ...
... Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) ... rodent and primate, repeat-dose toxicology studies with L-DOS47.   ... expanded number of rodent and primate test animals, building ... studies.   The Company plans to conduct ...
... Inc. and Imanet (part of GE Healthcare) have ... clinical imaging. This agreement supports the development strategy ... agents based on recombinant antibody fragments. The Imanet™ ... provides assistance in all aspects of PET imaging-based ...
Cached Biology Technology:WAVE Conference and Exhibition 2011 Taking Products to Market incorporating Micro & Nano Technology 2Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions 2Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions 3ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research 2ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research 3
(Date:2/5/2015)... , January 28, 2015 New ... Size And Segment Forecasts To 2020 has Been Added ... camera market is expected to reach USD 5.10 billion ... View Research, Inc. IR cameras help identify the site ... expected to witness surging demand in medical imaging applications. ...
(Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... on Contact Metallic copper surfaces kill microbes ... in the February 2011 issue of the journal ... in minutes, by causing massive membrane damage after about ... Grass of the University of Nebraska, Lincoln. This is ...
... Qqest and M2SYS Technology, a global biometrics research and ... to offer TimeForce time and attendance customers the added ... their PC. M2SYS, RightPunch(TM) solution enables the ... interface with Qqest,s TimeForce time and attendance system, providing ...
... cancer, and development of new cancer therapeutics, has focused ... of focus is the life and death of a ... cell death, is a fundamental process of cells including ... involve many different proteins and their interactions with each ...
Cached Biology News:Tips from the journals of the American Society for Microbiology 2Tips from the journals of the American Society for Microbiology 3Tips from the journals of the American Society for Microbiology 4Tips from the journals of the American Society for Microbiology 5Tips from the journals of the American Society for Microbiology 6Tips from the journals of the American Society for Microbiology 7Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3Designing new molecular tools to study the life and death of a cancer cell 2Designing new molecular tools to study the life and death of a cancer cell 3Designing new molecular tools to study the life and death of a cancer cell 4
... Continuous flow of media and other fluid ... lab space, The speed of each individual ... flow set points, are exactly maintained. ... with variable tube types, which allows flow ...
...
... Application: Pyronin Y is most ... green to selectively and differentially stain ... In a dichromatic dye solution, Pyronin ... green stains DNA green. ...
... designed for the fast and simple integration ... any position (for the generation of transgenic ... designed to allow neomycin / kanamycin selection ... a prokaryotic promoter (gb2) for expression of ...
Biology Products: